Pet ownership constantly increases and nowadays people are considering their cat or dog as a member of the family. As pets live longer, they develop similar geriatric and civilization diseases as humans but there is a gap in the availability of innovative and specific treatments for serious diseases or chronic conditions in companion animals.

Our mission is to develop novel, species-specific therapeutic antibodies from our proprietary, and state of the art antibody platform. The whole team is very passionate identifying unmet medical needs and supporting veterinary health professionals as well as pet owners in treating dogs & cats with novel highly efficient drugs.

Antibody selection is based on a novel fully synthetic and species-specific phage display technology. Currently used strategies rely on the modification of a single existing molecule in a process that is laborious and prone to failure.  Our platform allows the de-novo identification of a panel of antibodies to select the best in class drug candidate with optimal functionality, developability and low risk of immunogenicity. Our primary goal is to address the medical need in canines, but the technology will be adapted at later stages to other species such as cats or horses.

In addition to our own drug development, we are planning collaborations with pharmaceutical partners from the veterinary field.